Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

January 15, 2028

Conditions
Relapsed Advanced Lymphomas
Interventions
DRUG

AUR112

Once daily

Trial Locations (18)

110017

ACTIVE_NOT_RECRUITING

Max Super Specialty Hospital, Saket

110029

ACTIVE_NOT_RECRUITING

AIIMS, New Delhi, New Delhi

124105

RECRUITING

National Cancer Institute , All India Institute of Medical Sciences, Jhajjar

249203

RECRUITING

AIIMS, Rishikesh, Rishikesh

302019

ACTIVE_NOT_RECRUITING

Somani Hospital, Jaipur

390001

RECRUITING

Sir Sayajirao General Hospital (SSG), Vadodara

400012

ACTIVE_NOT_RECRUITING

Tata Memorial Hospital, Pārel

410014

ACTIVE_NOT_RECRUITING

Sahyadri Hospital Private Limited, Pune

411014

RECRUITING

Novo Solitaire Care, Pune

415519

RECRUITING

Onco Life Cancer, Centre, Satara, Satara

431001

RECRUITING

Jeevan Amrut Hematology Center, Aurangabad, Aurangabad

440026

ACTIVE_NOT_RECRUITING

HCG Cancer Centre, Nagpur

442107

RECRUITING

Siddharth Gupta Memorial Hospital,, Wardha

560027

ACTIVE_NOT_RECRUITING

Health Care Global Enterprises, Bangalore

RECRUITING

Srinivasam Cancer Care Multi Speciality Hospitals India Pvt Ltd. , Bangalore 560072., Bangalore

700160

ACTIVE_NOT_RECRUITING

Tata Medical Centre, Kolkata

751019

RECRUITING

AIIMS, Bhubaneswar, Bhubaneswar

400 615

ACTIVE_NOT_RECRUITING

Sunact Cancer Institute Pvt. Ltd, Thāne

All Listed Sponsors
lead

Aurigene Discovery Technologies Limited

INDUSTRY